Skip to content

Public FDA record

Z-1128-2021: 13C-Spirulina Gastric Emptying Breath Test (GEBT) - Product Usage: intended for use in the measurement of

Recall record Z-1128-2021 for Cairn Diagnostics. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1128-2021
Company in FDA record
Cairn Diagnostics
FDA record creation date
Feb 16, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Potential for false negative diagnosis of gastroparesis. Certain GEBT kits containing 13C-Spirulina elicit unusually high 13CO2-excretion rates

Source facts

Action
The firm initiated the recall by telephone or email, followed with a telephone call on 01/08/2021. Commercial clients have been instructed not to use GEBT kits and that Cairn will follow up with a recall notice with full instructions on what to do with kits.
Initiated
2021-01-08
Root cause
Under Investigation by firm
Terminated
2023-08-09
Distribution
US Nationwide distribution in the states of GA, NY, MI, CA, KS, NC.
Recall number
Z-1128-2021
Recall status
Terminated
CDRH record ID
185506
FDA record created
2021-02-16
Recall event number
87186

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗